CEACAM5 and colorectal carcinoma: In a study by Parkhurst et al., the treatment of metastatic CRC with genetically engineered anti-carcinoembryonic antigen (CEA) T cells resulted in tumor regression in one individual but “serious inflammatory colitis” in all patients, demonstrating that an adverse autoimmune response is another possible consequence of targeting TAAs (10).